Search

Your search keyword '"Bonnefoi H"' showing total 448 results
Start Over Author "Bonnefoi H"
448 results on '"Bonnefoi H"'

1. Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B

Author

Marmé, F., Martin, M., Untch, M., Thode, C., Bonnefoi, H., Kim, S.-B., Bear, H., Mc Carthy, N., Gelmon, K., García-Sáenz, J.A., Kelly, C.M., Reimer, T., Valota, O., Toi, M., Rugo, H.S., Gnant, M., Makris, A., Bassy, M., Zhang, Z., Furlanetto, J., Nekljudova, V., and Loibl, S.

Published
2024
Full Text
View/download PDF

2. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial

Author

Penault-Llorca, F., Dalenc, F., Chabaud, S., Cottu, P., Allouache, D., Cameron, D., Grenier, J., Venat Bouvet, L., Jegannathen, A., Campone, M., Debled, M., Hardy-Bessard, A.-C., Giacchetti, S., Barthelemy, P., Kaluzinski, L., Mailliez, A., Mouret-Reynier, M.-A., Legouffe, E., Cayre, A., Martinez, M., Delbaldo, C., Mollon-Grange, D., Macaskill, E.J., Sephton, M., Stefani, L., Belgadi, B., Winter, M., Orfeuvre, H., Lacroix-Triki, M., Bonnefoi, H., Bliss, J., Canon, J.-L., Lemonnier, J., Andre, F., and Bachelot, T.

Published
2024
Full Text
View/download PDF

3. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

Author

Aebi, S., Al-Foheidi, M., André, F., Anikusko, M., Badwe, R., Barrio, A.V., Barrios, C., Bergh, J., Bonnefoi, H., Bretel Morales, D., Brucker, S., Burstein, H.J., Caldas, C., Cameron, D., Cardoso, F., Cardoso, M.J., Carey, L., Chia, S., Coles, C., Cortes, J., Curigliano, G., de Boniface, J., Delaloge, S., DeMichele, A., Denkert, C., Fastner, G., Fitzal, F., Francis, P., Gamal, H., Gentilini, O., Gnant, M., Gradishar, W., Gulluoglu, B., Harbeck, N., Heil, J., Huang, C.-S.H., Huober, J., Jiang, Z., Kaidar-Person, O., Kok, M., Lee, E.-S., Loi, S., Loibl, S., Martin, M., Meattini, I., Morrow, M., Partridge, A., Penault-Llorca, F., Piccart, M., Pierce, L., Poortmans, P., Regan, M., Reis-Filho, J., Rubio, I., Rugo, H., Rutgers, E., Saura, C., Senkus, E., Shao, Z., Singer, C., Spanic, T., Thuerlimann, B., Toi, M., Tolaney, S., Turner, N., Tutt, A., Vrancken Peeters, M.-J., Watanabe, T., Weber, W., Wildiers, H., Xu, B., Regan, M.M., Weber, W.P., and Thürlimann, B.

Published
2023
Full Text
View/download PDF

4. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Author

Luen, S.J., Viale, G., Nik-Zainal, S., Savas, P., Kammler, R., Dell’Orto, P., Biasi, O., Degasperi, A., Brown, L.C., Láng, I., MacGrogan, G., Tondini, C., Bellet, M., Villa, F., Bernardo, A., Ciruelos, E., Karlsson, P., Neven, P., Climent, M., Müller, B., Joshum, W., Bonnefoi, H., Martino, S., Davidson, N.E., Geyer, C., Chia, S.K., Ingle, J.N., Coleman, R., Solbach, C., Thürlimann, B., Colleoni, M., Coates, A.S., Goldhirsch, A., Fleming, G.F., Francis, P.A., Speed, T.P., Regan, M.M., and Loi, S.

Published
2023
Full Text
View/download PDF

8. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Author

Curigliano, G, Burstein, H.J., Winer, E.P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M.M., Piccart-Gebhart, M., Senn, H.-J., Thürlimann, B., André, F., Baselga, J., Bergh, J., Bonnefoi, H., Brucker, S.Y., Cardoso, F., Carey, L., Ciruelos, E., Cuzick, J., Denkert, C., Di Leo, A., Ejlertsen, B., Francis, P., Galimberti, V., Garber, J., Gulluoglu, B., Goodwin, P., Harbeck, N., Hayes, D.F., Huang, C.-S., Huober, J., Khaled, H., Jassem, J., Jiang, Z., Karlsson, P., Morrow, M., Orecchia, R., Osborne, K.C., Pagani, O., Partridge, A.H., Pritchard, K., Ro, J., Rutgers, E.J.T., Sedlmayer, F., Semiglazov, V., Shao, Z., Smith, I., Toi, M., Tutt, A., Viale, G., Watanabe, T., Whelan, T.J., and Xu, B.

Published
2017
Full Text
View/download PDF

10. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Author

Luen, SJ, Viale, G, Nik-Zainal, S, Savas, P, Kammler, R, Dell'Orto, P, Biasi, O, Degasperi, A, Brown, LC, Lang, I, MacGrogan, G, Tondini, C, Bellet, M, Villa, F, Bernardo, A, Ciruelos, E, Karlsson, P, Neven, P, Climent, M, Mueller, B, Jochum, W, Bonnefoi, H, Martino, S, Davidson, NE, Geyer, C, Chia, SK, Ingle, JN, Coleman, R, Solbach, C, Thurlimann, B, Colleoni, M, Coates, AS, Goldhirsch, A, Fleming, GF, Francis, PA, Speed, TP, Regan, MM, Loi, S, Luen, SJ, Viale, G, Nik-Zainal, S, Savas, P, Kammler, R, Dell'Orto, P, Biasi, O, Degasperi, A, Brown, LC, Lang, I, MacGrogan, G, Tondini, C, Bellet, M, Villa, F, Bernardo, A, Ciruelos, E, Karlsson, P, Neven, P, Climent, M, Mueller, B, Jochum, W, Bonnefoi, H, Martino, S, Davidson, NE, Geyer, C, Chia, SK, Ingle, JN, Coleman, R, Solbach, C, Thurlimann, B, Colleoni, M, Coates, AS, Goldhirsch, A, Fleming, GF, Francis, PA, Speed, TP, Regan, MM, and Loi, S

Abstract

BACKGROUND: Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+HER2-) early breast cancer (EBC) have higher rates of recurrence and death for reasons that remain largely unexplained. PATIENTS AND METHODS: Genomic sequencing was applied to HR+HER2- tumours from patients enrolled in the Suppression of Ovarian Function Trial (SOFT) to determine genomic drivers that are enriched in young premenopausal women. Genomic alterations were characterised using next-generation sequencing from a subset of 1276 patients (deep targeted sequencing, n = 1258; whole-exome sequencing in a young-age, case-control subsample, n = 82). We defined copy number (CN) subgroups and assessed for features suggestive of homologous recombination deficiency (HRD). Genomic alteration frequencies were compared between young premenopausal women (<40 years) and older premenopausal women (≥40 years), and assessed for associations with distant recurrence-free interval (DRFI) and overall survival (OS). RESULTS: Younger women (<40 years, n = 359) compared with older women (≥40 years, n = 917) had significantly higher frequencies of mutations in GATA3 (19% versus 16%) and CN amplifications (CNAs) (47% versus 26%), but significantly lower frequencies of mutations in PIK3CA (32% versus 47%), CDH1 (3% versus 9%), and MAP3K1 (7% versus 12%). Additionally, they had significantly higher frequencies of features suggestive of HRD (27% versus 21%) and a higher proportion of PIK3CA mutations with concurrent CNAs (23% versus 11%). Genomic features suggestive of HRD, PIK3CA mutations with CNAs, and CNAs were associated with significantly worse DRFI and OS compared with those without these features. These poor prognostic features were enriched in younger patients: present in 72% of patients aged <35 years, 54% aged 35-39 years, and 40% aged ≥40 years. Poor prognostic features [n = 584 (46%)] versus none [n = 692 (54%)] had an 8-year DRFI of 84% v

Published
2023

11. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Author

Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., Mousseau, M., Dauba, J., Del Piano, F., Desmoulins, I., Coussy, F., Madranges, N., Grenier, J., Bidard, F.C., Proudhon, C., MacGrogan, G., Orsini, C., Pulido, M., and Gonçalves, A.

Published
2016
Full Text
View/download PDF

13. 213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)

Author

Arnedos, M., primary, Goncalves, A., additional, Pulido, M., additional, Lerebours, F., additional, Tredan, O., additional, Dalenc, F., additional, Guiu, S., additional, Mollon Grange, D., additional, Teixeira, L., additional, Levy, C., additional, Verret, B., additional, Dawood, H.A.S., additional, Augereau, P., additional, Deiana, L., additional, Ladoire, S., additional, Carola, E., additional, Mouret Reynier, M.A., additional, Guyonneau, C., additional, MacGrogan, G., additional, and Bonnefoi, H., additional

Published
2022
Full Text
View/download PDF

14. LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)

Author

Buisseret, L., primary, Loirat, D., additional, Aftimos, P.G., additional, Punie, K., additional, Maurer, C., additional, Debien, V., additional, Goncalves, A., additional, Ghiringhelli, F., additional, Taylor, D., additional, Clatot, F., additional, van den Mooter, T.F.A., additional, Ferrero, J-M., additional, Bonnefoi, H., additional, Canon, J-L., additional, Duhoux, F.P., additional, Bazan, F., additional, Kristanto, P., additional, de Azambuja, E., additional, Ignatiadis, M., additional, and Piccart, M., additional

Published
2022
Full Text
View/download PDF

15. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Author

Bonnefoi, H., Litière, S., Piccart, M., MacGrogan, G., Fumoleau, P., Brain, E., Petit, T., Rouanet, P., Jassem, J., Moldovan, C., Bodmer, A., Zaman, K., Cufer, T., Campone, M., Luporsi, E., Malmström, P., Werutsky, G., Bogaerts, J., Bergh, J., and Cameron, D.A.

Published
2014
Full Text
View/download PDF

16. 241P Overall survival and updated invasive disease free survival results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after NACT

Author

Loibl, S., Jimenez, M. Martin, Bonnefoi, H., Untch, M., Kim, S-B., Bear, H.D., McCarthy, N.J., Gelmon, K.A., Saenz, J.Á. García, Kelly, C.M., Reimer, T., Zhang, Z., Toi, M., Rugo, H.S., Gnant, M.I., Makris, A., Debiasi, M., Hirmas, N., Nekljudova, V., and Marmé, F.

Published
2024
Full Text
View/download PDF

17. Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al.

Author

Dubsky, P, Curigliano, G, Burstein, H J, Winer, E P, Gnant, M, Loibl, S, Colleoni, M, Regan, M M, Piccart-Gebhart, M, Senn, H -J, Thürlimann, B, André, F, Baselga, J, Bergh, J, Bonnefoi, H, Brucker, S Y, Cardoso, F, Carey, L, Ciruelos, E, Cuzick, J, Denkert, C, Di Leo, A, Ejlertsen, B, Francis, P, Galimberti, V, Garber, J, Gulluoglu, B, Goodwin, P, Harbeck, N, Hayes, D F, Huang, C -S, Huober, J, Khaled, H, Jassem, J, Jiang, Z, Karlsson, P, Morrow, M, Orecchia, R, Osborne, K C, Pagani, O, Partridge, A H, Pritchard, K, Ro, J, Rutgers, E J T, Sedlmayer, F, Semiglazov, V, Shao, Z, Smith, I, Toi, M, Tutt, A, Viale, G, Watanabe, T, Whelan, T J, and Xu, B

Published
2018
Full Text
View/download PDF

20. Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)

Author

Buisseret, L., Loirat, D., Aftimos, P. G., Punie, K., Maurer, C., Debien, V., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., van den Mooter, T. F. A., Ferrero, J-M., Bonnefoi, H., Canon, J-L., Duhoux, F. P., Bazan, F., Kristanto, P., de Azambuja, E., Ignatiadis, M., Piccart, M., Buisseret, L., Loirat, D., Aftimos, P. G., Punie, K., Maurer, C., Debien, V., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., van den Mooter, T. F. A., Ferrero, J-M., Bonnefoi, H., Canon, J-L., Duhoux, F. P., Bazan, F., Kristanto, P., de Azambuja, E., Ignatiadis, M., and Piccart, M.

Published
2022

22. 8P An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy

Author

Blaye, C., primary, Darbo, E., additional, Debled, M., additional, Brouste, V., additional, Vélasco, V., additional, Pinard, C., additional, Pellegrin, I., additional, Tarricone, A., additional, Arnedos, M., additional, Commeny, J., additional, Bonnefoi, H., additional, Larmonier, C., additional, and Macgrogan, G., additional

Published
2022
Full Text
View/download PDF

25. Symptoms of endocrine treatment and outcome in the BIG 1-98 study

Author

Huober, J., Cole, B. F., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B., and for the BIG 1-98 Collaborative and International Breast Cancer Study Groups

Published
2014
Full Text
View/download PDF

27. 132P Health economic properties of palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy: Results from the Penelope-B trial

Author

Galactionova, K., primary, Loibl, S., additional, Salari, P., additional, Marmé, F., additional, Martin, M., additional, Untch, M., additional, Bonnefoi, H., additional, Kim, S-B., additional, Bear, H.D., additional, McCarthy, N., additional, Gelmon, K., additional, García-Saenz, J.A., additional, Kelly, C.M., additional, Reimer, T., additional, Toi, M., additional, Rugo, H.S., additional, Gnant, M., additional, Makris, A., additional, Burchardi, N., additional, and Schwenkglenks, M., additional

Published
2021
Full Text
View/download PDF

28. 122MO Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib

Author

García-Saenz, J.A., primary, Marmé, F., additional, Rugo, H.S., additional, Untch, M., additional, Bonnefoi, H., additional, Kim, S-B., additional, Bear, H.D., additional, McCarthy, N., additional, Gelmon, K., additional, Martin, M., additional, Kelly, C.M., additional, Reimer, T., additional, Toi, M., additional, Law, E.H., additional, Gnant, M., additional, Makris, A., additional, Seiler, S., additional, Burchardi, N., additional, Nekljudova, V., additional, and Loibl, S., additional

Published
2021
Full Text
View/download PDF

29. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

Author

Gourgou-Bourgade, S., Cameron, D., Poortmans, P., Asselain, B., Azria, D., Cardoso, F., AʼHern, R., Bliss, J., Bogaerts, J., Bonnefoi, H., Brain, E., Cardoso, M. J., Chibaudel, B., Coleman, R., Cufer, T., Dal Lago, L., Dalenc, F., De Azambuja, E., Debled, M., Delaloge, S., Filleron, T., Gligorov, J., Gutowski, M., Jacot, W., Kirkove, C., MacGrogan, G., Michiels, S., Negreiros, I., Offersen, B. V., Penault Llorca, F., Pruneri, G., Roche, H., Russell, N. S., Schmitt, F., Servent, V., Thürlimann, B., Untch, M., van der Hage, J. A., van Tienhoven, G., Wildiers, H., Yarnold, J., Bonnetain, F., Mathoulin-Pélissier, S., Bellera, C., and Dabakuyo-Yonli, T. S.

Published
2015
Full Text
View/download PDF

30. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

Author

Bonnefoi, H., Jacot, W., Saghatchian, M., Moldovan, C., Venat-Bouvet, L., Zaman, K., Matos, E., Petit, T., Bodmer, A., Quenel-Tueux, N., Chakiba, C., Vuylsteke, P., Jerusalem, G., Brain, E., Tredan, O., Messina, C. G. M., Slaets, L., and Cameron, D.

Published
2015
Full Text
View/download PDF

32. 309P Machine learning-based characterization of tumor-immune microenvironment at a spatial and multiplexed resolution in early breast cancer: A sub-study of the EORTC 10994/BIG 1-00 randomized phase III trial with long-term follow-up

Author

Zerdes, I., Matikas, A., Mezheyeuski, A., Acs, B., Johansson, H., Manikis, G., Boyaci, C., Boman, C.E., Poncet, C., Ignatiadis, M., Bai, Y., Rimm, D., MacGrogan, G., Cameron, D.A., Bergh, J., Bonnefoi, H., and Foukakis, T.

Published
2023
Full Text
View/download PDF

34. 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)

Author

Metzger, O., primary, Lambertini, C., additional, Krop, I.E., additional, Lewis Phillips, G., additional, Perou, C.M., additional, Symmans, F., additional, Melero, I., additional, Harbeck, N., additional, Winer, E.P., additional, Im, S-A., additional, Barrios, C.H., additional, Bonnefoi, H., additional, Gralow, J.R., additional, Ellis, P.A., additional, Gianni, L., additional, Toi, M., additional, Swain, S.M., additional, Boulet, T., additional, Song, C., additional, and de Haas, S., additional

Published
2021
Full Text
View/download PDF

41. Symptoms of endocrine treatment and outcome in the BIG 1-98 study

Author

Huober, J., Cole, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J., Neven, P., Láng, I., Smith, I., Wardley, A., Price, K., Goldhirsch, A., Coates, A., Colleoni, M., Gelber, R., Thürlimann, B., Huober, J., Cole, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J., Neven, P., Láng, I., Smith, I., Wardley, A., Price, K., Goldhirsch, A., Coates, A., Colleoni, M., Gelber, R., and Thürlimann, B.

Abstract

There may be a relationship between the incidence of vasomotor and arthralgia/myalgia symptoms and treatment outcomes for postmenopausal breast cancer patients with endocrine-responsive disease who received adjuvant letrozole or tamoxifen. Data on patients randomized into the monotherapy arms of the BIG 1-98 clinical trial who did not have either vasomotor or arthralgia/myalgia/carpal tunnel (AMC) symptoms reported at baseline, started protocol treatment and were alive and disease-free at the 3-month landmark (n=4,798) and at the 12-month landmark (n=4,682) were used for this report. Cohorts of patients with vasomotor symptoms, AMC symptoms, neither, or both were defined at both 3 and 12months from randomization. Landmark analyses were performed for disease-free survival (DFS) and for breast cancer free interval (BCFI), using regression analysis to estimate hazard ratios (HR) and 95 % confidence intervals (CI). Median follow-up was 7.0years. Reporting of AMC symptoms was associated with better outcome for both the 3- and 12-month landmark analyses [e.g., 12-month landmark, HR (95% CI) for DFS=0.65 (0.49-0.87), and for BCFI=0.70 (0.49-0.99)]. By contrast, reporting of vasomotor symptoms was less clearly associated with DFS [12-month DFS HR (95% CI)=0.82 (0.70-0.96)] and BCFI (12-month DFS HR (95% CI)=0.97 (0.80-1.18). Interaction tests indicated no effect of treatment group on associations between symptoms and outcomes. While reporting of AMC symptoms was clearly associated with better DFS and BCFI, the association between vasomotor symptoms and outcome was less clear, especially with respect to breast cancer-related events.

Published
2019

47. Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923)

Author

van Rijswijk, R.E.N., Vermorken, J.B., Reed, N., Favalli, G., Mendiola, C., Zanaboni, F., Mangili, G., Vergote, I., Guastalla, J.P., ten Bokkel Huinink, W.W., Lacave, A.J., Bonnefoi, H., Tumulo, S., Rietbroek, R., Teodorovic, I., Coens, C., and Pecorelli, S.

Published
2003
Full Text
View/download PDF

50. Detection of PIK3CA mutation by circulating DNA during chemotherapy: A tool to identify hard-to-treat metastatic breast cancers

Author

Mosele, F., primary, Lusque, A., additional, Tran Dien, A., additional, Droin, N., additional, Le Tourneau, C., additional, Sablin, M.P., additional, Lacroix, L., additional, Miran, I., additional, Jovelet, C., additional, Bieche, I., additional, Soria, J-C, additional, Bertucci, F., additional, Bonnefoi, H., additional, Campone, M., additional, Dalenc, F., additional, Bachelot, T., additional, Jacquet, A., additional, Jimenez, M., additional, and André, F., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results